Regeneron Pharmaceuticals
REGN
920.69
-1.71
-0.19%
Regeneron Pharmaceuticals
US · REGN
#285 by market cap
Listed 1970
920.69
-1.71
-0.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B+
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 3
■ Upgrades■ Downgrades
- 2 upgrades vs 3 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Hold to Buy on 2026-10-14.
Analyst consensus 23 analysts
Buy
Avg price target 959.57 +4.2%
Price target rangecurrent 920.69
Low761.00
Avg959.57
High1,175.00
Buy 70%
Hold 30%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-02 | CCORF | -- | Buy | 1,175.00 |
| 2026-11-02 | UBS | -- | Buy | 1,068.00 |
| 2026-11-02 | Truist Financial | -- | Buy | 982.00 |
| 2026-11-02 | BMO Capital | -- | Buy | 1,050.00 |
| 2026-11-02 | Guggenheim | -- | Buy | 1,100.00 |
| 2026-11-02 | Leerink Partners | -- | Hold | 997.00 |
| 2026-11-01 | Cantor Fitzgerald | -- | Buy | 980.00 |
| 2026-10-30 | Wells Fargo | -- | Hold | 925.00 |
| 2026-10-30 | Piper Sandler | -- | Buy | 1,000.00 |
| 2026-10-30 | Raymond James | -- | Buy | 1,020.00 |
| 2026-10-30 | BofA Securities | -- | Buy | 1,030.00 |
| 2026-10-30 | Morgan Stanley | -- | Hold | 855.00 |
| 2026-10-30 | Citi | -- | Hold | 825.00 |
| 2026-10-30 | RBC Capital | -- | Hold | 913.00 |
| 2026-10-30 | J.P. Morgan | -- | Buy | 1,050.00 |
| 2026-10-28 | CCORF | -- | Buy | 922.00 |
| 2026-10-27 | RBC Capital | -- | Hold | 810.00 |
| 2026-10-21 | TD Cowen | -- | Buy | 980.00 |
| 2026-10-21 | Leerink Partners | -- | Hold | 835.00 |
| 2026-10-20 | Leerink Partners | -- | Hold | 835.00 |
| 2026-10-19 | Piper Sandler | -- | Buy | 865.00 |
| 2026-10-16 | UBS | -- | Buy | 978.00 |
| 2026-10-15 | UBS | -- | Buy | 978.00 |
| 2026-10-14 | UBS | -- | Buy | 978.00 |
| 2026-10-14 | Scotiabank | -- | Hold | 770.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-14 | UBS | Hold → Buy | 978.00 |
| 2026-08-17 | Leerink Partners | Buy → Hold | 824.00 |
| 2026-05-17 | Citi | Buy → Hold | 700.00 |
| 2026-01-07 | BofA Securities | Sell → Buy | 860.00 |
| 2025-12-03 | Morgan Stanley | Buy → Hold | 767.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-30 | -- | ±5.70% | +13.33% (beat) |
| 2026/Q2 | 2026-07-30 | -- | ±5.74% | +6.17% (beat) |
| 2026/Q1 | 2026-04-29 | -- | ±6.78% | -6.21% (in line) |
| 2025/Q4 | 2026-01-30 | -- | ±6.18% | -1.07% (in line) |
| 2025/Q3 | 2025-10-28 | -- | ±5.28% | +11.82% (beat) |
| 2025/Q2 | 2025-08-01 | -- | ±8.36% | +2.46% (in line) |
| 2025/Q1 | 2025-04-29 | -- | ±5.87% | -6.87% (beat) |
| 2024/Q4 | 2025-02-04 | -- | ±5.57% | +4.53% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±3.92% | -9.17% (beat) |
| 2024/Q2 | 2024-08-01 | -- | ±4.99% | +1.29% (in line) |
| 2024/Q1 | 2024-05-02 | -- | ±4.24% | +3.78% (in line) |
| 2023/Q4 | 2024-02-02 | -- | ±3.84% | -1.32% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Regeneron Pharmaceuticals discussion 0 comments